Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Goldstein

Showing results (21-30 of 136) with videos related to

Pageof 14
Sort By:
JAMA Oncology|August 22, 2018
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework-ReplyOmer Ben-Aharon, Daniel A Goldstein
Nature Reviews. Clinical Oncology|April 9, 2021
Registration trials in countries without access to US standards of care - pitfalls of interpretationGarth W Strohbehn, Daniel A Goldstein
Therapeutic Advances in Gastroenterology|October 4, 2019
Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysisAmir Shlomai, Moshe Leshno, Daniel A Goldstein
Cancer|June 30, 2017
Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?Daniel A Goldstein, Usama Bilal, Vinay Prasad
Plos One|November 9, 2018
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysisAmir Shlomai, Moshe Leshno, Daniel A Goldstein
BMC Gastroenterology|November 18, 2024
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC dataTomer Meirson, Gal Markel, Daniel A Goldstein
The Oncologist|August 13, 2015
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?Daniel A Goldstein, Bassel F El-Rayes
Medical Oncology (Northwood, London, England)|October 31, 2018
Duration of adjuvant immunotherapy-biologic, clinical and economic considerationsIdo Stav, Bishal Gyawali, Daniel A Goldstein
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|November 13, 2012
Response to original research article, in press, corrected proof, ‘‘Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize’’Bruce Hammond, Daniel A Goldstein, David Saltmiras
Israel Journal of Health Policy Research|October 1, 2016
The cost and value of cancer drugs - are new innovations outpacing our ability to pay?Daniel A Goldstein, Salomon M Stemmer, Noa Gordon
Pageof 14

Showing results (21-30 of 136) with videos related to

Sort By:
Pageof 14
JAMA Oncology|August 22, 2018
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework-ReplyOmer Ben-Aharon, Daniel A Goldstein
Nature Reviews. Clinical Oncology|April 9, 2021
Registration trials in countries without access to US standards of care - pitfalls of interpretationGarth W Strohbehn, Daniel A Goldstein
Therapeutic Advances in Gastroenterology|October 4, 2019
Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysisAmir Shlomai, Moshe Leshno, Daniel A Goldstein
Cancer|June 30, 2017
Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?Daniel A Goldstein, Usama Bilal, Vinay Prasad
Plos One|November 9, 2018
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysisAmir Shlomai, Moshe Leshno, Daniel A Goldstein
BMC Gastroenterology|November 18, 2024
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC dataTomer Meirson, Gal Markel, Daniel A Goldstein
The Oncologist|August 13, 2015
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?Daniel A Goldstein, Bassel F El-Rayes
Medical Oncology (Northwood, London, England)|October 31, 2018
Duration of adjuvant immunotherapy-biologic, clinical and economic considerationsIdo Stav, Bishal Gyawali, Daniel A Goldstein
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|November 13, 2012
Response to original research article, in press, corrected proof, ‘‘Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize’’Bruce Hammond, Daniel A Goldstein, David Saltmiras
Israel Journal of Health Policy Research|October 1, 2016
The cost and value of cancer drugs - are new innovations outpacing our ability to pay?Daniel A Goldstein, Salomon M Stemmer, Noa Gordon
Pageof 14